Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer

(2021) Cheng-Hao Chuang et al.   Cancers

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor–Naive Advanced ALK-Positive Non–Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

(2021) D. Ross Camidge et al.   Journal of Thoracic Oncology

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis

(2021) Koichi Ando et al.   Cancers

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

(2021) Ling Peng et al.   Frontiers in Oncology

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis

(2020) Jesse Elliott et al.   PLoS One

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study

(2020) T. Mok et al.   ANNALS OF ONCOLOGY

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis

(2020) Koichi Ando et al.   Cancers

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

(2020) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study

(2019) D. Ross Camidge et al.   Journal of Thoracic Oncology

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

(2019) Caicun Zhou et al.   Lancet Respiratory Medicine

1484PDFinal PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

(2019) T S K Mok et al.   ANNALS OF ONCOLOGY

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

(2019) Maurice Pérol et al.   LUNG CANCER

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

(2018) S Gadgeel et al.   ANNALS OF ONCOLOGY

Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.

(2018) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

(2018) D. Ross Camidge et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Matching-Adjusted Indirect Comparison (MAIC) Of Crizotinib With Standard of Care In Progressed Nsclc ALK+ Patients Based On Real-World Evidence (RWE) And Clinical Trial Data In The Czech Republic

(2017) B Pasztor et al.   VALUE IN HEALTH

ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice

(2017) Paul Hofman   Cancers

Extended Survival and Prognostic Factors for Patients WithALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis

(2016) Kimberly L. Johung et al.   JOURNAL OF CLINICAL ONCOLOGY

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

(2016) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

(2015) Deepa Rangachari et al.   LUNG CANCER

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

(2014) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma

(2013) Hyo Jae Kang et al.   RESPIRATORY MEDICINE

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING